Actions

Per-protocol analysis: Difference between revisions

From TrialTree Wiki

Created page with "= Per-Protocol (PP) Analysis = '''Per-Protocol (PP) Analysis''' evaluates the effect of an intervention among participants who fully adhered to the assigned treatment protocol. In contrast to Intention-to-Treat (ITT) analysis, which includes all randomized participants regardless of adherence, PP analysis estimates the efficacy of an intervention under ideal conditions. == 1. When to Use Per-Protocol Analysis == PP analysis is particularly useful in specific scenarios..."
 
 
Line 1: Line 1:
= Per-Protocol (PP) Analysis =
= Per-Protocol (PP) Analysis =


'''Per-Protocol (PP) Analysis''' evaluates the effect of an intervention among participants who fully adhered to the assigned treatment protocol. In contrast to Intention-to-Treat (ITT) analysis, which includes all randomized participants regardless of adherence, PP analysis estimates the efficacy of an intervention under ideal conditions.
'''Per-Protocol (PP) [[Analysis]]''' evaluates the effect of an intervention among participants who fully adhered to the assigned treatment protocol. In contrast to Intention-to-Treat (ITT) analysis, which includes all randomized participants regardless of adherence, PP analysis estimates the efficacy of an intervention under ideal conditions.


== 1. When to Use Per-Protocol Analysis ==
== 1. When to Use Per-Protocol Analysis ==
Line 9: Line 9:
* When assessing the true biological or mechanistic effect of an intervention.
* When assessing the true biological or mechanistic effect of an intervention.
* In studies where adherence is essential to achieving the treatment effect (e.g., dietary or behavioral trials).
* In studies where adherence is essential to achieving the treatment effect (e.g., dietary or behavioral trials).
* As a complement to ITT analysis for sensitivity or subgroup analysis.
* As a complement to ITT analysis for sensitivity or [[subgroup analysis]].


''Example:'' In a diabetes drug trial, the ITT population includes all randomized participants, while the PP analysis includes only those who took ≥80% of their prescribed doses.
''Example:'' In a diabetes drug trial, the ITT population includes all randomized participants, while the PP analysis includes only those who took ≥80% of their prescribed doses.
Line 16: Line 16:


* '''Higher risk of bias''': Excluding non-adherent participants may introduce selection bias.
* '''Higher risk of bias''': Excluding non-adherent participants may introduce selection bias.
* '''Loss of randomization benefits''': Treatment groups may become unbalanced after exclusions.
* '''Loss of [[randomization]] benefits''': Treatment groups may become unbalanced after exclusions.
* '''Limited generalizability''': Findings apply only to those who followed the protocol and may not reflect real-world effectiveness.
* '''Limited generalizability''': Findings apply only to those who followed the protocol and may not reflect real-world effectiveness.


Line 50: Line 50:
* Clearly define the adherence criteria used.
* Clearly define the adherence criteria used.
* Report the number and proportion of participants excluded from the ITT population.
* Report the number and proportion of participants excluded from the ITT population.
* Compare PP and ITT results as part of a sensitivity analysis.
* Compare PP and ITT results as part of a [[sensitivity analysis]].




Line 56: Line 56:


Per-Protocol analysis estimates the ideal efficacy of an intervention but comes with a higher risk of bias. It should be interpreted cautiously and reported alongside ITT analyses as part of a comprehensive trial analysis. Pre-specifying adherence criteria is critical to maintain transparency and minimize bias.
Per-Protocol analysis estimates the ideal efficacy of an intervention but comes with a higher risk of bias. It should be interpreted cautiously and reported alongside ITT analyses as part of a comprehensive trial analysis. Pre-specifying adherence criteria is critical to maintain transparency and minimize bias.
----
=== Bibliography ===
# Gupta SK. Intention-to-treat concept: a review. ''Perspectives in Clinical Research''. 2011;2(3):109–112. Discusses both intention-to-treat and per-protocol approaches.
# Montori VM, Guyatt GH. Intention-to-treat principle. ''CMAJ''. 2001;165(10):1339–1341. Includes discussion of when per-protocol analysis may be considered.
# White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for [[intention-to-treat analysis]] in randomised trials with missing outcome data. ''BMJ''. 2011;342:d40. Reviews limitations and alternatives including per-protocol.
# Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed as observational studies. ''Annals of Internal Medicine''. 2013;159(8):560–562. Critiques naive per-protocol analysis and suggests causal modeling approaches.
# Piantadosi S. Clinical Trials: A Methodologic Perspective. 3rd ed. Wiley; 2017. Chapter on protocol adherence and analysis strategies, including per-protocol and as-treated analysis.
----
''Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.''

Latest revision as of 11:55, 4 June 2025

Per-Protocol (PP) Analysis

Per-Protocol (PP) Analysis evaluates the effect of an intervention among participants who fully adhered to the assigned treatment protocol. In contrast to Intention-to-Treat (ITT) analysis, which includes all randomized participants regardless of adherence, PP analysis estimates the efficacy of an intervention under ideal conditions.

1. When to Use Per-Protocol Analysis

PP analysis is particularly useful in specific scenarios:

  • When assessing the true biological or mechanistic effect of an intervention.
  • In studies where adherence is essential to achieving the treatment effect (e.g., dietary or behavioral trials).
  • As a complement to ITT analysis for sensitivity or subgroup analysis.

Example: In a diabetes drug trial, the ITT population includes all randomized participants, while the PP analysis includes only those who took ≥80% of their prescribed doses.

2. Key Considerations

  • Higher risk of bias: Excluding non-adherent participants may introduce selection bias.
  • Loss of randomization benefits: Treatment groups may become unbalanced after exclusions.
  • Limited generalizability: Findings apply only to those who followed the protocol and may not reflect real-world effectiveness.

3. Steps for PP Analysis

1. Define adherence criteria: This should be outlined in the study protocol. Examples include minimum medication adherence (e.g., ≥80%), attendance at a specified number of therapy sessions, or completion of follow-up assessments. 2. Exclude non-adherent participants: Participants who crossed over to another group, missed major follow-up points, or deviated from the protocol are excluded. 3. Analyze the per-protocol population: Conduct statistical analysis using only those who met the adherence threshold.

4. Statistical Methods for PP Analysis

  • Continuous outcomes: Use t-tests, linear regression, or mixed-effects models.
  • Binary outcomes: Apply logistic regression or estimate relative risk.
  • Time-to-event outcomes: Use Kaplan–Meier survival analysis or Cox proportional hazards models.

5. PP vs. ITT Analysis

Comparison of Per-Protocol and Intention-to-Treat Analysis
Aspect Per-Protocol (PP) Intention-to-Treat (ITT)
Population Only adherent participants All randomized participants
Effect Estimate Efficacy (ideal conditions) Effectiveness (real-world)
Bias Risk Higher (due to exclusions) Lower (preserves randomization)
Clinical Relevance Lower Higher

6. Reporting PP Analysis in RCTs

  • Clearly define the adherence criteria used.
  • Report the number and proportion of participants excluded from the ITT population.
  • Compare PP and ITT results as part of a sensitivity analysis.


7. Conclusion

Per-Protocol analysis estimates the ideal efficacy of an intervention but comes with a higher risk of bias. It should be interpreted cautiously and reported alongside ITT analyses as part of a comprehensive trial analysis. Pre-specifying adherence criteria is critical to maintain transparency and minimize bias.


Bibliography

  1. Gupta SK. Intention-to-treat concept: a review. Perspectives in Clinical Research. 2011;2(3):109–112. Discusses both intention-to-treat and per-protocol approaches.
  2. Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001;165(10):1339–1341. Includes discussion of when per-protocol analysis may be considered.
  3. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention-to-treat analysis in randomised trials with missing outcome data. BMJ. 2011;342:d40. Reviews limitations and alternatives including per-protocol.
  4. Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed as observational studies. Annals of Internal Medicine. 2013;159(8):560–562. Critiques naive per-protocol analysis and suggests causal modeling approaches.
  5. Piantadosi S. Clinical Trials: A Methodologic Perspective. 3rd ed. Wiley; 2017. Chapter on protocol adherence and analysis strategies, including per-protocol and as-treated analysis.

Adapted for educational use. Please cite relevant trial methodology sources when using this material in research or teaching.